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Purpose: Controlled clinical trials evaluating the efficacy of repeated Waon therapy for patients 
with chronic obstructive pulmonary disease (COPD) have yet to be conducted. The purpose of 
the present study was to evaluate whether repeated Waon therapy exhibits an adjuvant effect 
on conventional therapy for COPD patients.
Patients and methods: This prospective trial comprised 20 consecutive COPD patients who 
satisfied the criteria of the Global initiative for chronic Obstructive Lung Disease (GOLD) guide-
lines, stages 1–4. They were assigned to either a Waon or control group. The patients in the Waon 
group received both repeated Waon therapy and conventional therapy,  including medications, 
such as long-acting inhaled β2 agonists, long-acting anticholinergics and  xanthine derivatives, 
and pulmonary rehabilitation. The Waon therapy consisted of sitting in a 60°C sauna room for 
15 minutes, followed by 30 minutes of being warmed with blankets once a day, 5 days a week, for a 
total of 20 times. The patients in the control group received only conventional therapy. Pulmonary 
function and the 6-minute walk test were assessed before and at 4 weeks after the program.
Results: The change in vital capacity (0.30 ± 0.4 L) and in peak expiratory flow (0.48 ± 0.79 L/s) in 
the Waon group was larger than the change in the vital capacity (0.02 ± 0.21 L) (P=0.077) and peak 
expiratory flow (−0.11 ± 0.72 L/s) (P=0.095) in the control group. The change in forced  expiratory 
flow after 50% of expired forced vital capacity in the Waon group, 0.08 (0.01–0.212 L/s), was 
larger than that in the control group, −0.01 (−0.075–0.04 L/s) (P=0.019). Significant differences 
were not observed in the change in any parameters in the 6-minute walk test. Data are presented 
as means ± standard deviation or median (25th–75th percentile).　
Conclusion: The addition of repeated Waon therapy to conventional therapy for COPD patients 
can possibly improve airway obstruction.
Keywords: modified Borg scale, airway obstruction, 6-minute walk test, quality of life
Introduction
The number of patients diagnosed with chronic obstructive pulmonary disease (COPD) 
has been gradually increasing in Japan as the population ages. As various kinds of 
drugs, such as long-acting β2 agonists and long-acting anticholinergics, have come 
into wide use in recent years, the number of COPD patients who can live in a stable 
condition for many years has increased. However, pulmonary rehabilitation plays an 
irreplaceable role and is one of the most effective interventions in improving quality 
of life (QOL),1,2 exercise tolerance, and fatigue, for all COPD patients.3
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Especially in clinical practice, the purpose of  treatment 
for COPD patients is to improve certain respiratory 
 symptoms, such as dyspnea on exertion and coughing up 
of sputum. Improvement of symptoms can expand patients’ 
functional participation in activities of daily living and 
improve their QOL.
Some studies indicating that pulmonary rehabilitation 
improves QOL for COPD patients have been reported. 
Godoy et al4 reported that the benefits provided by a pul-
monary rehabilitation program, in terms of the indices of 
QOL as well as improved 6-minute walk test performance, 
persisted throughout the 24-month study period, in patients 
with COPD. Pulmonary rehabilitation does not always need 
to be conventional. Sindhwani et al5 reported that a domicili-
ary pulmonary rehabilitation program improved the QOL and 
exercise endurance of patients with severe COPD and acted 
as a substitute for conventional pulmonary rehabilitation 
programs in resource-limited situations. Effective pulmonary 
rehabilitation for COPD patients is not necessarily formulaic. 
For example, the study by Rae and White6 suggested that the 
swimming pool was a feasible and positive alternative venue 
for pulmonary rehabilitation, for COPD patients in primary 
care. These reports demonstrated that not only medication, 
but also, nondrug therapy, such as lung physical therapy 
or exercise therapy, is important for COPD patients and 
improves their QOL.
Tei et al7 were the first to report on hemodynamic changes 
in patients with congestive heart failure, during Waon therapy 
using a far infrared-ray dry sauna which is evenly maintained 
at 60°C.  Cardiovascular hemodynamics improved after a water 
bath or sauna, in patients with chronic heart failure due to 
ischemic or idiopathic dilated cardiomyopathy. Twenty-eight 
patients showed improvement in left and right ventricular 
functions, associated with reduction in afterload (total periph-
eral vascular resistance for the left ventricle and pulmonary 
vascular resistance for the right ventricle) on thermal vaso-
dilatation after Waon therapy. Warming was also expected 
to dilate the venous system (which decreases pulmonary 
congestion). The results indicated that cardiac index, stroke 
index, peripheral vascular resistance, and pulmonary artery 
pressure all significantly decreased during and for 30 min-
utes after Waon therapy. The duration of the effectiveness of 
Waon therapy has not been verified yet. Tei et al believed the 
endothelial nitric oxide synthase (eNOS) upregulation induced 
by the sauna was caused by increases in the cardiac output and 
blood flow, which in turn increased the shear stress.
In recent years in Japan, repeated Waon therapy has been 
put into practical use for patients with heart failure, as a 
nondrug therapy. Umehara et al reported that repeated Waon 
therapy improved pulmonary hypertension during exercise, 
in 13 patients with severe COPD.8 They found that the lowest 
oxygen saturation (SpO2) during exercise, as assessed by 
ergometer, was significantly elevated and that exercise time 
was also significantly increased after Waon therapy. We sup-
posed that the improvement of exercise tolerance with COPD 
after repeated Waon therapy might be associated with an 
improvement of airway obstruction in addition to improved 
pulmonary hypertension.
There have been no controlled clinical trials to evaluate the 
effectiveness of repeated Waon therapy as a nondrug therapy 
for COPD patients. The purpose of the present study was to 
evaluate whether repeated Waon therapy could exhibit an 
added effect to conventional therapies for COPD patients.
Patients and methods
Patients
The study population comprised 20 consecutive inpatients 
and outpatients with COPD (age range 50–80 years) who 
 satisfied the criteria of the Global initiative for chronic 
Obstructive Lung Disease (GOLD) guidelines for stages 1–4.3 
Subjects who had suffered from acute exacerbation, left-
side heart  failure, and who were unable to walk because of 
 arteriosclerosis obliterans or knee osteoarthritis within the 
month prior to the study were excluded. Subjects who went 
into respiratory distress and needed to receive additional 
therapy or who had difficulty walking because of leg pain 
during the study were also excluded.
Waon therapy
As previously reported by Tei et al,7 a far infrared ray dry 
sauna; whole body hyperthermia application (dry system) 
(NOMS Corporation, Aichi, Japan) was used for the Waon 
therapy. The patients were seated in a 60°C sauna room for 
15 minutes, and after leaving the sauna, they rested on a bed 
while covered with a blanket to keep warm, for an additional 
30 minutes. The patients were weighed before and after sauna 
bathing, and oral hydration with water was used to compen-
sate for lost weight. Repeated Waon therapy was performed 
once a day, 5 days a week (from Monday through Friday), 
for 4 weeks, for a total of 20 times.8,9
Conventional therapy
For conventional therapy, the subjects were approved to 
receive medical treatment for COPD, including long-acting 
β2 agonists (LABA), long-acting anticholinergics, xanthine 
derivatives (oral theophyllines), inhaled glucocorticoids 
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(alone or in combination with LABA) and systemic 
glucocorticoids, and pulmonary rehabilitation, such as 
 walking, swimming training, ergometer exercise, and respi-
ratory training. However new medications and pulmonary 
rehabilitation programs are assumed to start up to 2 weeks 
before the study. They have been instructed not to change 
their program during this study.
Pulmonary function test
Vital capacity (VC), forced vital capacity (FVC), forced 
expiratory volume in 1 second (FEV
1
), forced expiratory flow 
after 50% of expired FVC (FEF
50
), forced expiratory flow after 
75% of expired FVC (FEF
25
), and peak expiratory flow (PEF) 
were measured in all subjects, using a spirometer (Chestac 
33; Chest Co, Tokyo, Japan) linked to a computer.
exercise tolerance
The functional status, evaluated as exercise tolerance, 
was assessed using the 6-minute walk test (6MWT). The 
6MWT followed the pulmonary function test according to a 
standardized protocol.10 It is now the most commonly used 
timed walking test11,12 that can predict the risk of death in 
COPD patients.13,14 The distance walked in 6 minutes has 
been accepted as a good outcome measure after interven-
tions such as pulmonary rehabilitation.15 In our study, the 
6MWT was carried out in a hospital corridor with a length 
of 100 m. The subjects were allowed to slow down or stop 
if needed but were required to resume walking as soon as 
they felt able. They were given feedback on the elapsed time 
each minute and were encouraged to continue walking. All 
subjects were informed of the details of the 6MWT and how 
it worked. Dyspnea, as measured with the modified Borg dys-
pnea scale,16 oxygen saturation, and pulse rate were assessed 
at the start and end of the 6MWT. Oxygen saturation was 
measured using a Wrist OxTM (Model 3100; Star Product, 
Tokyo, Japan).
study protocol
The COPD patients were alternately assigned in the enroll-
ment sequence to either the Waon or control group; the 
former received repeated Waon therapy plus conventional 
therapy, while the latter received only conventional therapy. 
The physician explained the study protocol and obtained 
 written informed consent from all participants prior to 
 assigning the patients to the regimen.
The study protocol was approved by the Ethics  Committee 
of the Faculty of Medicine, Okayama University. This 
clinical trial is registered with the University Hospital 
Medical Information Network clinical trials registry (number 
UMIN000004391).
To rule out any acute effects of Waon therapy, the 
pulmonary test and 6MWT were performed before the first 
treatment and on the day after the last treatment.8 The out-
come measured first was pulmonary function, and then the 
6MWT was measured.
statistical analysis
All data were expressed as absolute value, means ± SD, 
or median (25th–75th percentile). An unpaired t-test or 
Mann−Whitney test was used for comparison between 
the groups. The statistical analysis was performed using 
SPSS version 16.0 J for Windows (SPSS Inc, Chicago, IL, 
USA), and P-values,0.05 were considered statistically 
significant.
Results
Patients
Table 1 shows the demographic characteristics, smoking 
history, degree of severity of respiratory function impair-
ment, and typical therapeutic regimen for COPD patients. 
No important differences were seen between the two groups, 
in these characteristics or therapeutic regimens. A total of 
20 patients were alternately assigned to each group. Our study 
program lasted at least 4 weeks, so only two outpatients were 
able to participate in each group. The study was performed 
from April 2010 to May 2011, at Misasa Medical Center, 
Okayama University Hospital, Tottori, Japan.
Table 1 Baseline demographics of the study groups
Waon 
(n=10)
Control 
(n=10)
Male/female 9/1 9/1
age, years 70.3 ± 5.8 73.6 ± 6.1
smoking status
 Former 10 10
 Current 0 0
 Pack years 56 (27–94) 57 (34–103)
FeV1, % pred 54.1 ± 14.7 63.2 ± 26.6
resting spO2, % 95.6 ± 1.8 95.9 ± 0.7
height 162.4 ± 5.0 160.4 ± 4.6
BMI, kg/m2 22.3 ± 2.4 23.0 ± 2.4
Medication use
 long-acting anticholinergics 8 6
 long-acting β2 agonist 9 8
 Xanthine derivatives 7 7
lung physical therapy 10 10
Note: Data are absolute numbers, presented as means ± sD or median (25th−75th 
percentile).
Abbreviations: sD, standard deviation; FeV1, forced expiratory volume in 1 
second; spO2, oxygen saturation; BMI, body mass index. 
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exercise tolerance
All the parameters for the 6MWT are shown in Table 2. 
A significant between-group difference was not observed in 
the change in any parameters of the 6MWT.
Pulmonary function
Table 3 shows the change in ventilator parameters at baseline 
and after 4 weeks. Figures 1–3 show the changes in VC, PEF, 
and FEF
50
, respectively. The change in VC (0.30 ± 0.4 L) in 
the Waon group was larger than that in the control group 
(0.02 ± 0.21 L) (P=0.077), as shown in Figure 1. The change 
in PEF (0.48 ± 0.79 L/s) in the Waon group was larger than 
that in the control group (−0.11 ± 0.72 L/s) (P=0.095), as 
shown in Figure 2. A significant between-group difference 
was observed in the changes in FEF
50
, which was larger 
in the Waon group (0.08 L/s [0.01–0.212 L/s]) than in the 
control group (−0.01 L/s [−0.075–0.04 L/s]) (P=0.019), as 
shown in Figure 3. By comparison, there was no significant 
difference in the change in FEV
1
 between the Waon group 
(0.12 ± 0.23 L) and the control group (−0.14 ± 0.12 L) 
(P=0.120). There was also no significant difference in the 
change in FVC between the Waon group (0.17 ± 0.44 L) 
and the control group (−0.06 ± 0.37 L) (P=0.233). Fur-
thermore, there was no significant difference in the change 
in FEF
25
 between the Waon group (0.03 L/s [−0.03–0.057 
L/s]) and the control group (0.01 L/s [−0.075–0.032 L/s]) 
(P=0.208).
Discussion
The goal of this study was to evaluate the effect of repeated 
Waon therapy for COPD patients. The changes in VC, PEF, 
and FEF
50
 in the Waon group were statistically larger than 
those in the control group. Notably, a significant between-
group difference was observed in the changes in FEF
50
. 
These results indicate that the combination of repeated Waon 
therapy and conventional therapies may be beneficial for 
comprehensive COPD treatment, from the aspect of improv-
ing airway obstruction, which in turn improves exercise 
tolerance in patients with COPD.
COPD is characterized by a progressive worsening of 
airflow limitation, associated with abnormally inflamed 
airways in older smokers. Leukocytes recruited to the lung 
contribute to COPD pathology by releasing reactive  oxygen 
metabolites and proteolytic enzyme.17 Thus, the larger 
improvement of VC, PEF, and FEF
50
 after repeated Waon 
therapy in our results was speculated to result from the sup-
pression of airway inflammation and the alleviation of airway 
obstruction after repeated Waon therapy; the expansibility of 
lung parenchyma might also be heightened. In 2001, Ikeda 
et al demonstrated that repeated Waon therapy upregulated 
arterial eNOS expression in Syrian golden hamsters18 and 
that eNOS expression and nitric oxide (NO) also increased in 
cardiomyopathic hamsters with heart failure.19 In a pilot study 
of 13 consecutive patients with severe COPD, Umehara et al8 
found that repeated Waon therapy significantly improved 
pulmonary hypertension  during exercise. They surmised 
Table 2 Changes in the 6-minute walk test, at baseline and after 
4 weeks
Waon 
(n=10)
Control 
(n=10)
Maximum Borg scale
 at baseline 3.0 (1.6–7.0) 3.5 (1.8–5.5)
 after 4 weeks 2.0 (0.37–5.0) 2.5 (0.9–7.0)
Walk distance (m)
 at baseline 287 ± 131 291 ± 114
 after 4 weeks 333 ± 106 310 ± 110
Minimum spO2 (%)
 at baseline 88 ± 5 85 ± 4
 after 4 weeks 89 ± 5 87 ± 5
Maximum heart rate (beats/min)
 at baseline 112 ± 20 101 ± 15
 after 4 weeks 109 ± 26 107 ± 15
Note: Data are presented as means ± sD or median (25th−75th percentile).
Abbreviations: sD, standard deviation; spO2, oxygen saturation.
Table 3 Change in ventilatory parameters, at baseline and after 
4 weeks
Waon 
(n=10)
Control 
(n=10)
PeF (l/s)
 at baseline 3.08 ± 0.999 3.85 ± 1.543
 after 4 weeks 3.56 ± 1.478 3.73 ± 1.64
FeF50 (l/s)
 at baseline 0.37 (0.31–0.71) 0.50 (0.26–0.82)
 after 4 weeks 0.52 (0.29–0.82) 0.52 (0.24–0.77)
FeF25 (l/s)
 at baseline 0.17 (0.15–0.27) 0.22 (0.16–0.31)
 after 4 weeks 0.21 (0.12–0.33) 0.22 (0.17–0.28)
VC (l)
 at baseline 2.87 ± 0.68 2.90 ± 0.65
 after 4 weeks 3.16 ± 0.69 2.92 ± 0.63
FVC (l)
 at baseline  2.6 ± 0.764 2.71 ± 0.936
 after 4 weeks 2.77 ± 0.969 2.65 ± 0.869
FeV1 (l)
 at baseline 1.22 ± 0.43 1.34 ± 0.66
 after 4 weeks 1.35 ± 0.56 1.32 ± 0.644
Notes: Data are presented as means ± sD or median (25th−75th percentile).
Abbreviations: SD, standard deviation; PEF, peak expiratory flow; FEF50, forced 
expiratory flow after 50% of expired FVC; FEF25, forced expiratory flow after 75% of 
expired FVC; VC, vital capacity; FVC, forced vital capacity; FeV1, forced expiratory 
volume in 1 second; l, liter; l/s, liter per second.
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Figure 1 amount of change in VC for each patient for the pulmonary function test. 
Notes: aP=0.077 compared with the control, analyzed by unpaired t-test. Data are presented as means ± sD. 
Abbreviations: sD, standard deviation; VC, vital capacity; l, liter.
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Figure 2 amount of change in PeF for each patient for the pulmonary function test. 
Notes: bP=0.095 compared with the control, analyzed by unpaired t-test. Data are presented as means ± sD. 
Abbreviations: SD, standard deviation; PEF, peak expiratory flow; L/s, Liter per second.
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Figure 3 amount of change in FeF50 for each patient for the pulmonary function test. 
Notes: cP=0.019 compared with control, analyzed by Mann–Whitney test. Data are presented as median (with ranges in parentheses, 25th–75th percentile). 
Abbreviations: FeF50, forced expiratory flow after 50% of expired forced vital capacity; L/s, Liter per second.
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that Waon therapy increased the expression of eNOS in the 
pulmonary artery and improved pulmonary artery vascular 
function. However, it is unclear whether repeated Waon 
therapy influences the level of NO in the airway; it is possible 
that repeated Waon therapy influences the level of NO in the 
airway of COPD patients.
Many studies investigating NO and pulmonary function 
parameters have been reported. Ansarin et al demonstrated 
that among patients with COPD, exhaled NO was inversely 
correlated with FEV
1
, further suggesting a relationship 
between NO production and bronchoconstriction.20  Moreover, 
Tadié et al reported that nitric oxide synthase 2, one of the 
isoforms that produces NO, seems to be involved in a con-
striction response to airway stretch.21 Brindicci et al22 studied 
47 patients with different severities of COPD, as determined 
by the GOLD guidelines. They found that COPD severity was 
correlated with an increased steady-state alveolar or periph-
eral NO concentration regardless of the patient’s smoking 
habit or current treatment. Moreover, McCurdy et al showed 
that in patients with GOLD stages 3 and 4 COPD, periph-
eral NO correlated with functional status, and large airway 
NO parameters correlated with health status. In this study, 
worsening global health status and increasing subjective 
symptoms were associated with increasing airway NO flux.23 
Our study did not evaluate the airway inflammation using NO 
flux in the airway before and after the program, but from the 
results of various studies, we speculated that the level of NO 
in the airway was decreased after repeated Waon therapy and 
that decreased NO flux influenced the relaxation of airway 
smooth muscles and alleviated airway obstruction.
The improvement of subjective symptoms is of par-
ticular importance in the evaluation of COPD treatment. 
This study was the first controlled clinical trial to evaluate 
repeated Waon therapy, using both the 6MWT and pulmonary 
 function test.
The 6-minute walk distance is often intercorrelated with 
QOL for COPD patients. Mangueira et al found that health-
related QOL (HRQOL) presented a negative correlation with 
the 6-minute walk distance and a positive correlation with the 
sensation of dyspnea and fatigue, as measured by the Borg 
scale, in a cross-sectional study involving 30 women with 
COPD.24 Umehara et al8 reported in a pilot study, that repeated 
Waon therapy significantly improved St George’s Respiratory 
Questionnaire scores and prolonged the mean exercise time in 
the constant load cycle ergometer exercise test, in patients with 
severe COPD. In contrast, the grades on the Medical Research 
Council dyspnea scale, which measures dyspnea severity, did 
not change.25 In our controlled clinical trial as well, dyspnea 
did not show a significant between-group difference as shown 
in the change in the maximum Borg scale score (P=0.147).
This study did have several limitations. The sample size 
was small, and an obvious selection bias was present due 
to the study being nonrandomized and unblinded. Thus, 
the results in this study evaluating the effect of repeated Waon 
therapy should only be viewed as preliminary. Further studies 
are needed to investigate not only exercise tolerance and pul-
monary function, but also, the changes in biological markers, 
such as the NO flux, in order to understand the mechanism 
of improvement of airway obstruction. The investigation of 
the changes in NO flux before and after Waon therapy may 
provide insight into the association between repeated Waon 
therapy and airflow limitation.
Over the 4-week study period, none of the patients 
assigned to the study experienced arrhythmias, angina, or 
respiratory distress during Waon therapy or the conventional 
therapy. There were no incidences of nontolerance of the 
therapies.
In conclusion, this study provides new information on 
the effect of repeated Waon therapy for patients with COPD. 
The results obtained in this study show that the addition of 
repeated Waon therapy to conventional therapy for COPD 
patients could be useful for improving airway obstruction 
and might reduce dyspnea on exertion.
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